Navigation Links
Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
Date:11/19/2009

SEATTLE, Nov. 19 /PRNewswire-FirstCall/ -- Omeros Corporation (Nasdaq: OMER) today announced unaudited financial results for the third quarter ended September 30, 2009. For the three months ended September 30, 2009, Omeros reported a net loss of $3.9 million, or $1.34 per share, as compared to a net loss of $7.4 million, or $2.54 per share, for the same period in 2008. For the nine months ended September 30, 2009, the Company reported a net loss of $15.5 million, or $5.29 per share, as compared to a net loss of $17.4 million, or $6.07 per share, for the same period in 2008.

On October 7, 2009, Omeros priced its initial public offering (IPO), which generated net proceeds to the Company of approximately $61.8 million from the sale of 6,820,000 shares of its common stock at a price of $10.00 per share.

"Our IPO afforded Omeros the resources to advance aggressively our pipeline of clinical and preclinical programs. We expect that the proceeds will allow us to complete our ongoing Phase 3 clinical trials for our lead PharmacoSurgery(TM) product, OMS103HP, and fund its commercial launch into the arthroscopy market. We also recently amended a key agreement for our GPCR program, providing us with additional opportunities to realize the value of the program while limiting our expenditures," said Gregory A. Demopulos, M.D., Chairman and CEO of Omeros. "Throughout the course of next year, we look forward to releasing data from our Phase 3 arthroscopic program as well as meeting additional clinical milestones for our ophthalmologic and urologic programs."

Financial Results

Total operating expenses for the three months ended September 30, 2009 were $5.0 million compared to $8.2 million for the same period in 2008. The decrease in operating expenses in the third quarter of 2009 as compared to the same peri
'/>"/>

SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
2. Omeros Appoints David A. Mann to its Board of Directors
3. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
4. Omeros and BlueCrest Announce $20 Million Debt Facility
5. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
6. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
7. Omeros Appoints New Vice President of Clinical Development
8. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
9. Omeros Commences Initial Public Offering of Common Stock
10. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
11. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Oct. 1, 2014 Pfanstiehl has announced ... EP), manufactured in the USA ... long been recognized for playing a key role ... body of evidence that media supplementation with mannose ... protein glycosylation," according to Dr. Christopher Wilcox ...
(Date:10/1/2014)... 30, 2014 The participants committed to ... to spending their own time adjusting, tweaking and testing ... designs were ready for judging. , “I enjoyed being ... thought leader. “The entries showed a commendable range ... characteristics of the print medium and the creativity of ...
(Date:10/1/2014)... September 30, 2014 In response ... tools to address sales, training and consumer engagement ... developed innovative mobile applications to turn their clients’ ... agency’s latest customized mobile app creations, are now ... , In partnership with Toyota, StudioPMG created a ...
(Date:10/1/2014)... (PRWEB) September 30, 2014 Award ... SoundConnect announces four new-hosted collaboration bundles that ... deliver high quality conferencing experiences for low, flat ... to choose from, businesses have optimized solutions to ... solutions include audio only minutes (1K, 5K, ...
Breaking Biology Technology:Pfanstiehl Launches cGMP-produced Mannose for Cell Culture Media Optimization & Glycoprotein Biosynthesis 2Array Architects Challenges Staff to Create with 3D Printer 2Digital Agency Studio PMG Launches New Case Studies on Website 2SoundConnect Launches New Audio, Web and Video Bundles 2
... Sabila Industrial Originally Certified ISO in January 2003 ... Any Company They Audited Performed at Such a ... High Quality Level" ... - Company Dedicated to Quality, IRVING, Texas, Sept. 6 Carrington,Laboratories, Inc. (Pink ...
... Allergan, Inc. has partnered with fashion designer Kara ... Faces in Fashion on a campaign called,"Project: Sweat ... medical,condition called severe primary axillary hyperhidrosis or excessive,underarm ... on women,s lifestyle,choices, as well as available treatment ...
... NPS,Pharmaceuticals, Inc. (Nasdaq: NPSP ) announced today that ... all of its outstanding 3.0% Convertible,Notes due 2008. The ... 4, 2007, unless extended. The tender offer, which is ... letter of transmittal, is not,subject to the receipt of ...
Cached Biology Technology:Carrington Reports on ISO 9001:2000 Inspection at Sabila Industrial in Costa Rica 2Carrington Reports on ISO 9001:2000 Inspection at Sabila Industrial in Costa Rica 3MultiVu Video Feed: Allergan, Inc. Partners With "Project Runway" Designer Kara Saun and Gen Art Fresh Faces In Fashion to Raise Awareness About Excessive Underarm Sweating 2NPS Pharmaceuticals Commences Tender Offer for 3.0% Convertible Notes Due 2008 2NPS Pharmaceuticals Commences Tender Offer for 3.0% Convertible Notes Due 2008 3NPS Pharmaceuticals Commences Tender Offer for 3.0% Convertible Notes Due 2008 4
(Date:9/30/2014)... have completed the first comprehensive numerical simulation of skeletal ... in an image as data points for the computer ... led by J.S. Chen, the William Prager Professor of ... UC San Diego, presented their findings on the development ... this month. Chen also gave a keynote speech about ...
(Date:9/30/2014)... September 30, 2014--Sea monkeys have captured the popular attention ... easily observable life cycle -- sold as dehydrated eggs, ... given little more than a tank of salt water. ... pattern: Like other zooplankton, brine shrimp vertically migrate in ... closer to the surface at night and retreating deeper ...
(Date:9/30/2014)... to tetrachloroethylene (PCE) in drinking water may increase ... to a new study led by a Boston ... study, published in the journal Environmental Health ... pregnancies among 1,766 women in Cape Cod, Ma., ... to the early 1980s by the installation of ...
Breaking Biology News(10 mins):First comprehensive meshfree numerical simulation of skeletal muscle tissue achieved 2Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2Contaminated water linked to pregnancy complications, BU study finds 2
... VA. (Jan. 25, 2012) --- A comprehensive investigation of ... forward in our understanding of how cocoa flavanols work ... benefits. Through the development of improved analytical methods, this ... of flavanols, which calls into question the reliability of ...
... -- Research!America,s Board chair, former Congressman John Edward Porter ... investment in basic research. , "America,s leadership is ... investments in discovery and development," said Porter. "We ... and Europe integrate science and technology into economic growth ...
... and aims to help residential, commercial and industrial building owners ... guide them through the best materials to use. ... research into practice by trialling a white roof on its ... talk about the energy consumption benefits of white roofs and ...
Cached Biology News:Recent study by Mars, Incorporated and partners underscores importance of metabolism in understanding health benefits of cocoa flavanols 2State of the Union speech: Promising outlook for research and innovation 2White roofs to make for cooler Melbourne buildings 2